Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MEDHAT M OSMAN

Allopathic & Osteopathic Physicians Nuclear Medicine

NPI
1932117819
CMS profile
359701
Location
ST LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$122,912.23

103 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Progenics Pharmaceuticals, Inc. $121,212.23 102
Blue Earth Diagnostics Limited $1,700.00 1

Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MEDHAT M OSMAN

NPI 1932117819 · CMS profile ID 359701

Allopathic & Osteopathic Physicians / Nuclear Medicine

ST LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1932117819?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MEDHAT M OSMAN, NPI 1932117819, CMS profile ID 359701. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1932117819?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). MEDHAT M OSMAN, NPI 1932117819, CMS profile ID 359701. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1932117819?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
MEDHAT M OSMAN, NPI 1932117819, CMS profile ID 359701, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 103 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1932117819?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

103 matching records · $122,912.23 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 103 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 103.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Progenics Pharmaceuticals, Inc. $139.0008/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112605 CMS
Progenics Pharmaceuticals, Inc. $204.0608/24/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112607 CMS
Progenics Pharmaceuticals, Inc. $63.0908/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112609 CMS
Progenics Pharmaceuticals, Inc. $4,440.0008/11/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112595 CMS
Progenics Pharmaceuticals, Inc. $24.6708/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112597 CMS
Progenics Pharmaceuticals, Inc. $80.0008/11/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112599 CMS
Progenics Pharmaceuticals, Inc. $55.0008/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112601 CMS
Progenics Pharmaceuticals, Inc. $4,440.0008/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112531 CMS
Progenics Pharmaceuticals, Inc. $121.5008/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112533 CMS
Progenics Pharmaceuticals, Inc. $1,201.8008/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112535 CMS
Progenics Pharmaceuticals, Inc. $606.0008/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112537 CMS
Progenics Pharmaceuticals, Inc. $90.0008/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112593 CMS
Progenics Pharmaceuticals, Inc. $1,110.0007/28/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991111993 CMS
Progenics Pharmaceuticals, Inc. $23.9807/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991111995 CMS
Progenics Pharmaceuticals, Inc. $4,440.0007/27/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991107495 CMS
Progenics Pharmaceuticals, Inc. $112.6107/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991107497 CMS
Progenics Pharmaceuticals, Inc. $25.0007/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991107499 CMS
Progenics Pharmaceuticals, Inc. $75.0007/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991107501 CMS
Progenics Pharmaceuticals, Inc. $317.3907/27/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991107777 CMS
Progenics Pharmaceuticals, Inc. $121.9907/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991107489 CMS
Progenics Pharmaceuticals, Inc. $20.0007/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991107491 CMS
Progenics Pharmaceuticals, Inc. $587.2707/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991107493 CMS
Progenics Pharmaceuticals, Inc. $1,110.0007/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112469 CMS
Progenics Pharmaceuticals, Inc. $4,440.0007/26/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112471 CMS
Progenics Pharmaceuticals, Inc. $861.8007/26/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112689 CMS
Progenics Pharmaceuticals, Inc. $4,440.0007/13/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112253 CMS
Progenics Pharmaceuticals, Inc. $839.4007/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112255 CMS
Progenics Pharmaceuticals, Inc. $576.0007/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112461 CMS
Progenics Pharmaceuticals, Inc. $37.5507/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112463 CMS
Progenics Pharmaceuticals, Inc. $221.8807/13/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112465 CMS
Progenics Pharmaceuticals, Inc. $124.9907/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991112467 CMS
Progenics Pharmaceuticals, Inc. $1,110.0006/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108905 CMS
Progenics Pharmaceuticals, Inc. $4,440.0006/22/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108935 CMS
Progenics Pharmaceuticals, Inc. $2,016.0006/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991111825 CMS
Progenics Pharmaceuticals, Inc. $92.6706/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991111827 CMS
Progenics Pharmaceuticals, Inc. $4,440.0005/10/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108665 CMS
Progenics Pharmaceuticals, Inc. $141.1705/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108667 CMS
Progenics Pharmaceuticals, Inc. $260.0005/10/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108669 CMS
Progenics Pharmaceuticals, Inc. $111.1205/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108671 CMS
Progenics Pharmaceuticals, Inc. $4,440.0003/23/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108607 CMS
Progenics Pharmaceuticals, Inc. $661.8103/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108609 CMS
Progenics Pharmaceuticals, Inc. $122.1303/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108611 CMS
Progenics Pharmaceuticals, Inc. $25.7003/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108633 CMS
Progenics Pharmaceuticals, Inc. $174.4503/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108635 CMS
Progenics Pharmaceuticals, Inc. $449.2403/23/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108637 CMS
Progenics Pharmaceuticals, Inc. $4,440.0003/21/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108151 CMS
Progenics Pharmaceuticals, Inc. $527.9703/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108153 CMS
Progenics Pharmaceuticals, Inc. $93.8403/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108155 CMS
Progenics Pharmaceuticals, Inc. $1,018.0003/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108171 CMS
Progenics Pharmaceuticals, Inc. $71.0003/21/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991108173 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,250.11 2
PY2022 $41,203.86 42
PY2023 $122,912.23 103
PY2024 $108,983.02 84
PY2025 $70,865.69 69

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $420,725.89 17
PY2024 Principal investigator $269,655.51 7
PY2023 Principal investigator $632,650.87 8
PY2022 Principal investigator $79,658.82 7
PY2021 Principal investigator $134,914.95 27
PY2020 Principal investigator $99,016.34 17
PY2019 Principal investigator $169,184.70 43

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

17 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,618.58 12/01/2025 Non-covered Recipient Entity
SSM HEALTH SAINT LOUIS UNIVERSITY HOSPITAL
LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor No dispute reported 06/30/2026 1190308804
Principal investigator 1 Novartis Pharmaceuticals Corporation $294.88 11/15/2025 Non-covered Recipient Entity
SSM HEALTH SAINT LOUIS UNIVERSITY HOSPITAL
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190308768
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,172.95 09/26/2025 Non-covered Recipient Entity
SSM HEALTH SAINT LOUIS UNIVERSITY HOSPITAL
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in Mainte No dispute reported 06/30/2026 1190308800
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $37,150.00 09/10/2025 Non-covered Recipient Entity
Saint Louis University
Phase 1/1b single arm, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC) No dispute reported 06/30/2026 1235994091
Principal investigator 1 Novartis Pharmaceuticals Corporation $179.55 06/24/2025 Non-covered Recipient Entity
VA MEDICAL CENTER
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190305083
Principal investigator 1 Eli Lilly and Company $5,850.00 06/03/2025 Non-covered Recipient Entity
VANDEVENTER PLACE RESEARCH FOUNDATION
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) No dispute reported 06/30/2026 1187893540
Principal investigator 1 Novartis Pharmaceuticals Corporation $35,300.00 04/15/2025 Non-covered Recipient Entity
ST LOUIS UNIVERSITY
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in Mainte No dispute reported 06/30/2026 1190300555
Principal investigator 1 Novartis Pharmaceuticals Corporation $181.34 04/15/2025 Non-covered Recipient Entity
VA MEDICAL CENTER
An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) No dispute reported 06/30/2026 1190305085
Principal investigator 1 Novartis Pharmaceuticals Corporation $505.42 03/15/2025 Non-covered Recipient Entity
SSM HEALTH SAINT LOUIS UNIVERSITY HOSPITAL
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190308770
Principal investigator 1 Novartis Pharmaceuticals Corporation $96.04 03/15/2025 Non-covered Recipient Entity
VA MEDICAL CENTER
An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) No dispute reported 06/30/2026 1190313437
Principal investigator 1 Novartis Pharmaceuticals Corporation $226,973.76 03/10/2025 Non-covered Recipient Entity
SSM HEALTH SAINT LOUIS UNIVERSITY HOSPITAL
A Phase Ib Dose Finding Study Assessing Safety and Activity of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Extensive Stage Small Cell Lung Cancer (ES-SCLC) in Combination With Carboplatin, Etoposide and Tislelizumab in Induction and With Tislelizumab in Mainte No dispute reported 06/30/2026 1190308802
Principal investigator 1 Eli Lilly and Company $16,117.22 02/18/2025 Non-covered Recipient Entity
SAINT LOUIS UNIVERSITY
Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH) No dispute reported 06/30/2026 1187889928
Principal investigator 1 Novartis Pharmaceuticals Corporation $18,748.00 02/04/2025 Non-covered Recipient Entity
ST LOUIS UNIVERSITY
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190300557
Principal investigator 1 Novartis Pharmaceuticals Corporation $41,682.03 02/01/2025 Non-covered Recipient Entity
SSM HEALTH SAINT LOUIS UNIVERSITY HOSPITAL
LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor No dispute reported 06/30/2026 1190308764
Principal investigator 1 Novartis Pharmaceuticals Corporation $325.80 01/27/2025 Non-covered Recipient Entity
VA MEDICAL CENTER
An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) No dispute reported 06/30/2026 1190313435
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,135.32 01/15/2025 Non-covered Recipient Entity
VA MEDICAL CENTER
An International Prospective Open-label, Multi-center, Randomized Phase III Study comparing [177Lu] Lu-PSMA-617 versus Observation to delay castration or disease recurrence in adult male patients with PSMA positive Oligometastatic Prostate Cancer (OMPC) No dispute reported 06/30/2026 1190313439
Principal investigator 1 Novartis Pharmaceuticals Corporation $395.00 01/01/2025 Non-covered Recipient Entity
SSM HEALTH SAINT LOUIS UNIVERSITY HOSPITAL
LuMIERE: A Phase 1/2, Multicenter, Open-label, Non-randomized Study to Investigate Safety and Tolerability, Pharmacokinetics, Dosimetry, and Preliminary Activity of 177Lu-FAP-2286 in Patients With an Advanced Solid Tumor No dispute reported 06/30/2026 1190308766